Formulation of benznidazole-lipid nanocapsules: Drug release, permeability, biocompatibility, and stability studies.

导出 LinkOut

翻译打印收藏纠错

作者： Eva C,Arrua ^[1] ; Olga,Hartwig ^[2] ; Brigitta,Loretz ^[3] ; Xabier,Murgia ^[3] ; Duy-Khiet,Ho ^[3] ; Guillaume,Bastiat ^[4] ; Claus-Michael,Lehr ^[2] ; Claudio J,Salomon ^[5]

作者单位： Institute of Chemistry, IQUIR-CONICET, National Council Research, Suipacha 531, 2000 Rosario, Argentina. ^[1] Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, 66123 Saarbruecken, Germany; Department of Pharmacy, Saarland University, 66123 Saarbruecken, Germany. ^[2] Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Saarland University, 66123 Saarbruecken, Germany. ^[3] LUNAM Université, Micro et Nanomédecines Biomimétiques, F-49933 Angers, France; Inserm, U1066 IBS-CHU, 4 rue Larrey, F-49933 Angers Cédex 9, France. ^[4] Institute of Chemistry, IQUIR-CONICET, National Council Research, Suipacha 531, 2000 Rosario, Argentina; Pharmacy Department, Faculty of Pharmaceutical and Biochemical Sciences, National University of Rosario, Suipacha, 531, 2000 Rosario, Argentina. Electronic address: csalomon@fbioyf.unr.edu.ar. ^[5]

关键词 Benznidazole Chagas disease Lipid nanocapsules Neglected tropical diseases Trypanosoma cruzi

主题词纳米囊(Nanocapsules);脂类(Lipids);通透性(Permeability);药物稳定性(Drug Stability)

DOI 10.1016/j.ijpharm.2023.123120

PMID 37307960

发布时间 2023-07-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交